AUTOMATED PAP TEST SCREENING FOR QUALITY CONTROL

在这项研究中，主要目标是开发一种自动颈椎 宫颈薄层人工筛查后的涂片分析系统 作为质量控制(QC)工具的标本。该装置将测量 被称为“恶性肿瘤相关改变”(MACs)的核特征 人工方法假阴性的样本中的疾病。在 在目前的技术水平和目前的监管环境下， 该系统的开发将在实验室中发挥重要的作用 质量，并很可能在自动化初选之前很久就进入市场 筛查设备。Mac的使用是新的和创新的，因为它允许 以非常合理的系统成本进行快速、准确的处理。同相 将开发和测试一个完全自动化的原型。特定的 研究领域：1)着色剂的优化；2)染料的使用 多焦平面，3)分类器的优化，4)完成 以及一台完全自动化的原型的测试。规格和设计 商业票据的使用将在第二阶段结束时开始并继续 进入第三阶段。 拟议的商业应用：该设备将提供增强的 所有细胞学实验室巴氏试验分析的质量控制 全世界。目前对10%的阴性涂片重新筛查的做法是 还不够。快速、廉价的自动化系统的实施 在人工筛选后使用将导致更高的准确性和 改善了医疗保健。

In this research, the primary goal is to develop an automated cervical smear analysis system for use after manual screening of thinlayer cervical specimens as a quality control (QC) instrument. The device will measure nuclear features termed "Malignancy Associated Changes" (MACs) to identify disease in samples that are falsely negative by manual methods. At the current levels of technology and in the present regulatory environment, the development of such a system will play an important role in laboratory quality, and will likely reach the market long before an automated primary screening device. The use of MACs is new and innovative in that it allows fast and accurate processing at a very reasonable system cost. In Phase II a fully automated prototype would be developed and tested. Specific research areas are 1) the optimization of the stain, 2) the use of multiple focal planes, 3) optimization of classifiers, and 4) completion and testing of a completely automated prototype. Specification and design of a commercial instrument will begin at the end of Phase II and continue into Phase III. PROPOSED COMMERCIAL APPLICATION: This device would provide enhanced quality control for Pap test analysis in all cytology laboratories worldwide. The current practice of rescreening 10% of negative smears is not adequate. Implementation of a fast and inexpensive automated system used after manual screening would result in increased accuracy and improved healthcare.